AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 42 min read$AVR

Knight Susan Elizabeth purchased $102K of AVR

Knight Susan Elizabeth purchased 11,000 shares of Anteris Technologies Global Corp. (AVR) at $9.29 ($0.10M total) on 2026-06-02.

Original reporting
SEC EDGAR · Knight Susan Elizabeth
Published Jun 4, 2026, 10:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$AVR
Bullish
medium confidence
Mentioned
$AVR
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVRBullishLow
01

Why it matters

The transaction may be interpreted as confidence in the stock, but it does not change fundamentals on its own without additional company-specific news.

02

Market read

Traders may use the buy as a small sentiment input, but it is unlikely to be a standalone driver of price action.

03

What to watch

No 10b5-1 plan is cited, but the article also provides no context on prior holdings, motivation, or whether other insiders are buying/selling.

Relevance 6/10Novelty 6/10Timing: Filed after-hours on 2026-06-04; reflects purchase dated 2026-06-02.

Background

The article is an SEC Form 4 disclosure of an insider’s open-market purchase by a director.

Company-level read

Ticker impact

$AVRBullishMedium confidence
Context

Director Susan Elizabeth Knight bought 11,000 shares of Anteris Technologies Global Corp. at $9.2935/share via open-market purchase.

Expected impact

Likely limited/short-lived price impact; may slightly improve near-term sentiment rather than drive a trend.

Evidence & confidence

The filing is a Form 4 insider transaction with a disclosed buy price and size, but no accompanying corporate event (earnings, guidance, deal, or regulatory action) is mentioned.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated sector-wide catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buys can be routine (e.g., diversification, compensation-related liquidity) and may not signal near-term upside.

Key entities

  • issuer
    Anteris Technologies Global Corp.

    Subject of the Form 4 insider purchase disclosure (AVR).

  • insider
    Susan Elizabeth Knight

    Director who purchased 11,000 shares on 2026-06-02.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AVR insider trading history →

Related articles

AUG 12
$AVRMed

Anteris Advances DurAVR Toward Commercialization; PARADIGM Trial Expands U.S. Recruitment

Anteris Technologies Global Corp. (AVR) reported Q2 2026 results and said it secured U.S. Medicare reimbursement eligibility for PARADIGM Trial procedures. The company began U.S. recruitment, with first patients treated in May 2026, and said the trial is recruiting in the U.S., Denmark and the Netherlands. Net operating cash outflow was $20.8M; R&D expense was $23.4M.

rttnews.com5 min
AUG 12
$AVRMed

Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway

Anteris Technologies (ASX:AVR, NASDAQ:AVR) said it advanced its pivotal PARADIGM Trial in the June quarter, enrolling and treating its first US patients after CMS Medicare reimbursement eligibility for qualifying procedures. Recruitment expanded to the US, Denmark and the Netherlands, with Canada and France receiving regulatory clearance. The trial targets about 1,000 patients. Net operating cash outflows were US$20.8m.

proactiveinvestors.com.au4 min
AUG 11
$AVRMedAI 8/10

Anteris Technologies Announces Results for the Second Quarter of 2026

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) reported Q2 2026 results for the quarter ended June 30, 2026. It said CMS granted Medicare reimbursement eligibility for the PARADIGM Trial, U.S. recruitment began with first patients treated in May 2026, and the trial expanded to multiple regions. Net operating cash outflows were $20.8M; R&D expenses were $23.4M.

leaderpost.com6 min
AUG 11
$AVRLow

Anteris Technologies Global Corp. (AVR): Results of Operations and Financial Condition

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anteris Technologies Announces Results for the Second Quarter of 2026 MINNEAPOLIS, United States and BRISBANE, Australia August 12, 2026 (AEST) Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committe

SEC EDGAR 8-K4 min
JUN 4
$AVRMed

Anteris Technologies Global (NASDAQ:AVR) Shares Up 12.6% – Should You Buy?

Anteris Technologies Global (NASDAQ:AVR) shares rose 12.6% to $10.0750 on Thursday, after closing at $8.95; the stock traded between $9.71 and $10.0750. Volume was 176,960 shares, down 84% vs. average. Analysts cited mixed views: Barclays raised its target to $18 (overweight), while Wall Street Zen moved to hold; consensus target is $16. In its May 12 earnings, the company reported -$0.28 EPS vs -$0.27 expected on $0.49M revenue vs $0.77M.

tickerreport.com5 min